|
ARHGAP21 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.05520003845783E-09 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.64390723256247E-12 |
| Stage1-vs-Stage2 |
3.008000E-01 |
| Stage1-vs-Stage3 |
1.294990E-01 |
| Stage1-vs-Stage4 |
1.819150E-01 |
| Stage2-vs-Stage3 |
7.052400E-02 |
| Stage2-vs-Stage4 |
6.908500E-02 |
| Stage3-vs-Stage4 |
9.064400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.69059999999277E-07 |
| Normal-vs-Asian |
7.07150005219148E-10 |
| Caucasian-vs-AfricanAmerican |
3.276800E-01 |
| Caucasian-vs-Asian |
1.395200E-01 |
| AfricanAmerican-vs-Asian |
9.069800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.22044604925031E-16 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
4.915800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(81-100Yrs) |
9.78550000000356E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.496780E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.380200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.274000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.710800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.883800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.781000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.520600E-03 |
| Classical-VS-Follicular |
7.568800E-01 |
| Classical-VS-Other |
1.716970E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
2.458100E-02 |
| Tall-VS-Other |
9.933400E-01 |
| Tall-VS-Normal |
2.44249065417534E-14 |
| Follicular-VS-Other |
2.250200E-01 |
| Follicular-VS-Normal |
1.65079061531515E-12 |
| Other-VS-Normal |
2.36710000000029E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
4.19331236400922E-13 |
| N0-vs-N1 |
6.627200E-01 |
|
|
